Qureight: Revolutionizing Drug Development with Data Curation
Qureight is at the forefront of redefining precision medicine through its AI-enabled data curation capabilities. This powerful tool is specifically designed to accelerate drug development at key decision points, making a significant impact in the field of healthcare.
In the realm of drug development, data curation is of utmost importance. Qureight excels in this area by working with a diverse range of entities, including biopharma, contract research organisations, and hospitals. By curating data from these sources, Qureight helps get the best drugs approved quickly, especially in the context of lung and heart diseases, which present significant challenges and opportunities.
One of the key features of Qureight is its AI-powered technology stack. This enables collaborative analysis of various types of data, such as imaging, clinical data, and biomarkers. For instance, the platform runs AI-based data analytics on complex healthcare data, including clinical trial images, physiological data, and blood-based biomarkers. Its proprietary technology includes ML-based image algorithms for CT scans, AI-assisted workflows, and central image reads with cloud-based technology.
Qureight also offers a connected view of disease. Its ML models are backed up and built through real-world data accessed through global partner healthcare institutions. This ensures that data from clinical trials is structured and available to pharmaceutical clients in real time. Collaborations with partner hospitals for real-world data curation and analysis allow for the collaborative solving of complex research problems.
Furthermore, Qureight is purpose-built by world-leading healthcare experts. It offers zero-footprint medical imaging viewing with the ability for annotation and ML model runs in the cloud. It also provides fast, efficient, and AI-guided central read image workflows for clinical trials, as well as the ability to generate synthetic study arms and access to a Key Opinion Leaders network. In addition, Qureight's AI-powered quantitative imaging analysis of CT scans includes quantification of lung volumes, airways, pulmonary vessels, and fibrosis.
The current diseases of interest for Qureight include interstitial lung diseases, pulmonary hypertension, and lung cancer. These diseases present unique challenges, and Qureight's data curation and analysis capabilities are crucial in addressing them. For example, interstitial lung diseases are a group of diseases that cause scarring and damage to the lung tissue, making diagnosis and monitoring difficult. Pulmonary hypertension is an umbrella term for a group of conditions that cause increased pressure in the heart/lung vascular circuit, and monitoring it can be challenging. Lung cancer is one of the most common and fatal types of cancer, and treatments can have various side effects.
Qureight has gained the trust of its partners, who recognize its value in helping them develop life-changing drugs. Partners such as AstraZeneca, Vicore Pharma AB, and Clario have praised Qureight for its ability to harness data and technology to push the boundaries of science and deliver meaningful insights that can improve patient outcomes.
